Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04724837 · ClinicalTrials.gov registry record · Phase 2
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
NCT04724837 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 542 participants.
The verdict
NCT04724837, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
Study Summary
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Zibotentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04724837
The ClinicalTrials.gov registry entry for NCT04724837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 542 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04724837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04724837 about?
NCT04724837 is a clinical study titled "Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)". The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and u...
What is the current status of trial NCT04724837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2021-04-28. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04724837?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Zibotentan (DRUG).
Who is sponsoring clinical trial NCT04724837?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.